Harvard Bioscience Shares Plunge, Molecular Devices Up

With shares of Harvard Bioscience dropping 13 percent, and Bio-Rad falling 11 percent, the BioCommerce Week Index this week ended down for the third time in the last four weeks.

Harvard Bioscience has lost 19 percent of its market capitalization in the last two weeks while Bio-Rad saw a 9-percent gain last week reversed this week.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.